TIBSOVO (ivosidenib tablets) is the only targeted therapy that was studied in a phase 3 trial specifically designed for newly diagnosed patients with mIDH1 AML

Meaningful
Clinical Results

Review key efficacy endpoints from the TIBSOVO AML clinical trials, including survival, response, and remission data.1

See Efficacy

Test
to Inform

A positive IDH1 mutation test can help guide the next treatment decision for appropriate patients with AML.1

Target mIDH1

NCCN Guidelines®
Recommendation

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommends ivosidenib (TIBSOVO) + AZA as an NCCN category 1 preferred treatment option for newly diagnosed patients ≥18 years of age with mIDH1 AML who are not candidates for intensive remission induction therapy.4

View
Recommendations

Give your patients the chance for improved outcomes–lead with TIBSOVO first in mIDH1 AML1

*As of January 2026.

AML, acute myeloid leukemia; AZA, azacitidine; CI, confidence interval; CR, complete remission; HR, hazard ratio; IC, induction chemotherapy; IDH1, isocitrate dehydrogenase‑1; mIDH1, mutated isocitrate dehydrogenase‑1; mOS, median overall survival; NCCN, National Comprehensive Cancer Network® (NCCN®); OS, overall survival; PBO, placebo; R/R, relapsed or refractory.

References: 1. Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2023. 2. Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300-305. doi:10.1021/acsmedchemlett.7b00421 3. Montesinos P, Marchione DM, Récher C, et al. Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. Blood Adv. 2025. doi:10.1182/bloodadvances.2025016399 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.5.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed July 21, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
 

INDICATIONS

TIBSOVO is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test with:

Newly Diagnosed Acute Myeloid Leukemia (AML)

  • In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy
Indications & Important Safety Information

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME IN AML

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.